Pacer Advisors Inc. bought a new stake in shares of GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 40,717 shares of the pharmaceutical company’s stock, valued at approximately $1,756,000.

Other institutional investors have also recently modified their holdings of the company. FMR LLC boosted its position in GlaxoSmithKline PLC by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock worth $996,452,000 after buying an additional 2,482,009 shares in the last quarter. Fisher Asset Management LLC boosted its position in GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after buying an additional 564,519 shares in the last quarter. Bank of America Corp DE boosted its position in GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after buying an additional 934,928 shares in the last quarter. Federated Investors Inc. PA boosted its position in GlaxoSmithKline PLC by 22.7% in the second quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock worth $194,521,000 after buying an additional 833,501 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in GlaxoSmithKline PLC by 42.7% in the first quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock worth $185,593,000 after buying an additional 1,316,600 shares in the last quarter. Institutional investors own 8.99% of the company’s stock.

GlaxoSmithKline PLC (GSK) opened at 39.47 on Friday. The firm has a 50-day moving average of $40.70 and a 200 day moving average of $41.84. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.54. The firm has a market capitalization of $96.46 billion, a PE ratio of 38.77 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. Equities research analysts forecast that GlaxoSmithKline PLC will post $2.84 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a yield of 4.98%. The ex-dividend date is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is presently 197.00%.

COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/27/pacer-advisors-inc-invests-1-76-million-in-glaxosmithkline-plc-gsk.html.

A number of equities analysts recently issued reports on GSK shares. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 13th. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Tuesday, July 18th. Berenberg Bank upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. BidaskClub upgraded shares of GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a research report on Friday. Finally, TheStreet upgraded shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $44.67.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.